KR102739607B1 - 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 - Google Patents

카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 Download PDF

Info

Publication number
KR102739607B1
KR102739607B1 KR1020207013847A KR20207013847A KR102739607B1 KR 102739607 B1 KR102739607 B1 KR 102739607B1 KR 1020207013847 A KR1020207013847 A KR 1020207013847A KR 20207013847 A KR20207013847 A KR 20207013847A KR 102739607 B1 KR102739607 B1 KR 102739607B1
Authority
KR
South Korea
Prior art keywords
schizophrenia
pharmaceutical composition
aripiprazole
symptoms
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207013847A
Other languages
English (en)
Korean (ko)
Other versions
KR20200074157A (ko
Inventor
정찬미
황선관
이지원
장용구
Original Assignee
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오팜 주식회사 filed Critical 에스케이바이오팜 주식회사
Publication of KR20200074157A publication Critical patent/KR20200074157A/ko
Application granted granted Critical
Publication of KR102739607B1 publication Critical patent/KR102739607B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207013847A 2017-11-14 2018-11-13 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 Active KR102739607B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020170151253 2017-11-14
KR20170151253 2017-11-14
PCT/KR2018/013769 WO2019098634A1 (ko) 2017-11-14 2018-11-13 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물

Publications (2)

Publication Number Publication Date
KR20200074157A KR20200074157A (ko) 2020-06-24
KR102739607B1 true KR102739607B1 (ko) 2024-12-06

Family

ID=66539804

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013847A Active KR102739607B1 (ko) 2017-11-14 2018-11-13 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물

Country Status (11)

Country Link
US (3) US11116751B2 (https=)
EP (2) EP3711759B1 (https=)
JP (3) JP7355747B2 (https=)
KR (1) KR102739607B1 (https=)
CN (2) CN117064892A (https=)
AU (1) AU2018367733B2 (https=)
BR (1) BR112020009310A2 (https=)
ES (1) ES3015458T3 (https=)
IL (1) IL274437B2 (https=)
MX (1) MX2020004975A (https=)
WO (1) WO2019098634A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2017066590A1 (en) * 2015-10-16 2017-04-20 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127489A1 (en) * 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
WO2006048771A1 (en) * 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
EP1921073A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
PL2445890T3 (pl) 2009-06-22 2016-02-29 Sk Biopharmaceuticals Co Ltd Sposób wytwarzania estru (R)-1-arylo-2-tetrazoliloetylowego kwasu karbaminowego
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
RU2610169C2 (ru) * 2014-09-11 2017-02-08 Общество С Ограниченной Ответственностью "Валентек" ПРОИЗВОДНЫЕ 7-ФТОРО-8-ХЛОРО-5Н-ДИБЕНЗО[b, е][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ
WO2016044314A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
WO2016065586A1 (en) * 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Pyrazole, triazole and tetrazole orexin receptor antagonists
US9771335B2 (en) * 2015-07-31 2017-09-26 The Johns Hopkins University Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels
US11221329B2 (en) * 2015-10-30 2022-01-11 Lieber Institute, Inc. Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
KR102900173B1 (ko) * 2016-12-14 2025-12-12 에스케이바이오팜 주식회사 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도
JP7724776B2 (ja) * 2019-11-22 2025-08-18 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む経口用医薬組成物及びその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2017066590A1 (en) * 2015-10-16 2017-04-20 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Epilepsy Research, 2015, 제111권, 페이지 85-141 1부.*

Also Published As

Publication number Publication date
US20230321041A1 (en) 2023-10-12
RU2020119301A3 (https=) 2021-12-15
EP3711759A1 (en) 2020-09-23
CN111432813A (zh) 2020-07-17
US11717509B2 (en) 2023-08-08
KR20200074157A (ko) 2020-06-24
ES3015458T3 (en) 2025-05-05
IL274437A (en) 2020-06-30
EP4545140A3 (en) 2025-07-09
EP4545140A2 (en) 2025-04-30
BR112020009310A2 (pt) 2020-10-13
EP3711759C0 (en) 2025-03-19
US20210361622A1 (en) 2021-11-25
WO2019098634A1 (ko) 2019-05-23
MX2020004975A (es) 2020-08-24
CN111432813B (zh) 2024-01-09
CA3081226A1 (en) 2019-05-23
RU2020119301A (ru) 2021-12-15
EP3711759A4 (en) 2021-11-24
JP7355747B2 (ja) 2023-10-03
CN117064892A (zh) 2023-11-17
US11116751B2 (en) 2021-09-14
EP3711759B1 (en) 2025-03-19
JP2021503012A (ja) 2021-02-04
JP2023139233A (ja) 2023-10-03
AU2018367733A1 (en) 2020-05-21
AU2018367733B2 (en) 2024-06-20
JP2025090816A (ja) 2025-06-17
US20200281895A1 (en) 2020-09-10
IL274437B1 (en) 2024-05-01
IL274437B2 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
US20060204486A1 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
TWI426906B (zh) 治療精神分裂症的醫藥組成物
JP7082162B2 (ja) マイボーム機能不全の治療剤
KR101692578B1 (ko) 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
CN118078835A (zh) 用于夜间尿频的治疗剂
KR102900173B1 (ko) 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도
ES3047794T3 (en) Tablet for use in treating huntington's disease and method of making the same
KR102739607B1 (ko) 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물
CA3081226C (en) Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
RU2772465C2 (ru) Смесь, содержащая карбаматное соединение для предотвращения, облегчения или лечения шизофрении
EP3463357A1 (en) (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders
DK2437744T3 (en) The modulation of the KCNQ potassium channel activity for the treatment of psychiatric disorders and symptoms thereof
KR20220108123A (ko) 치매 환자의 행동 및 심리적 증상 치료
JP2023510082A (ja) 認知症患者における行動・心理症状を治療するための方法
KR20100022955A (ko) (티오) -카르바모일-시클로헥산 유도체 및 정신분열 치료 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200514

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240717

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241024

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241203

End annual number: 3

Start annual number: 1

PG1601 Publication of registration